CFM
TCRX icon

Catalyst Funds Management’s TScan Therapeutics TCRX Stock Holding History

Catalyst Funds Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,763
Closed -$56K – 560
2025
Q3 		$56K Buy
30,763
+12,763
+71% +$22.6K 0.01% 472
2025
Q2 		$26.1K Buy
+18,000
New +$26K 0.01% 411
2024
Q4 		– Sell
-3,200
Closed -$15.9K – 1168
2024
Q3 		$15.9K Buy
+3,200
New +$19.3K ﹤0.01% 1117

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Catalyst Funds Management's TCRX Position: Q4 2025 in Review

Catalyst Funds Management sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 30,763 shares — an estimated $56K sold.

Catalyst Funds Management first reported a position in TCRX in Q3 2024 and held it in 3 quarters. The position peaked at $56K in Q3 2025. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Catalyst Funds Management reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 30,763 TScan Therapeutics shares in Q4 2025, an estimated $56K.
  • Catalyst Funds Management first reported a position in TScan Therapeutics in Q3 2024 and held it in 3 quarters.
  • Catalyst Funds Management's TScan Therapeutics position peaked at $56K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.